

**Article type:** Review

**Combination therapy of psoriasis with methotrexate and other oral disease-modifying antirheumatic drugs: a systematic review**

**Running head:**

**methotrexate combination with DMARDs in psoriasis**

Tyng-Shiuan Hsieh,<sup>1</sup> and Tsen-Fang Tsai<sup>1</sup>

1. Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

**Corresponding author:** Tsen-Fang Tsai, M.D., Ph.D.

Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, No.7, Chung-Shan South Road,  
Taipei, Taiwan.

**E-mail:** tftsai@yahoo.com; **TEL:** +886-2-2312-3456 (#62141); **Fax:** +886-2-2393-4177

No.	Author	Study design (Subjects)	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Other considerations	Quality of evidence
1	AbuHilal et al. 2016 (Canada) [1]	Retrospective cohort study (n = 81)	Low	No	No	Low	Undetected	Large effect (+1)	Low
2	An et al. 2017 (China) [2]	Randomized trial (n = 39)	High	No	No	High	Undetected	Non-blinded	Very Low
3	Aydin et al. 2006 (Turkey) [4]	Prospective cohort study (n = 20)	High	No	No	High	Undetected	Non-blinded	Very Low
4	Singh and Singnarpi 2021 (India) [5]	Randomized non-blinded controlled trial (n = 133)	Low	No	No	Low	Undetected	Non-blinded	Low
5	Clark et al. 1999 (UK) [6]	Retrospective case series (n = 19)	High	No	No	High	Undetected	No control group	Very Low
6	Korstanje et al. 1990 (Netherlands) [9]	Retrospective case series (n=4)	High	No	No	High	Undetected	No control group	Very Low
7	Lowenthal et al. 2008 (US) [10]	Retrospective case series (n = 18)	High	No	No	High	Undetected	66.7% of patients discontinued study treatment	Very Low
8	Mohanan et al. 2014 (India) [11]	Retrospective cohort study (n = 18)	High	No	No	High	Undetected	No control group	Very Low

9	Rattanakaemakorn et al. 2021 (Thailand) [14]	Retrospective cohort study (n = 160)	Low	No	No	Low	Undetected	No untreated controls	Low
10	Shivers and Montanez-Wiscovich 2019 (US) [15]	Case report (n = 1)	High	No	No	High	Possible	Single case	Very Low
11	Wong and Geogouras 1999 (Australia) [16]	Case report (n = 1)	High	No	No	High	Possible	Single case	Very Low

1. AbuHilal, M., S. Walsh, and N. Shear, *Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study*. J Cutan Med Surg, 2016. **20**(4): p. 313-6.
2. An, J., et al., *The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis*. Pharmacol Res, 2017. **121**: p. 158-168.
3. Asiri, A., et al., *The effectiveness of leflunomide in psoriatic arthritis*. Clin Exp Rheumatol, 2014. **32**(5): p. 728-31.
4. Aydin, F., et al., *Methotrexate and ciclosporin combination for the treatment of severe psoriasis*. Clin Exp Dermatol, 2006. **31**(4): p. 520-4.
5. Singh, S.K. and S.R. Singnarpi, *Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial*. Indian J Dermatol Venereol Leprol, 2021. **87**(2): p. 214-222.
6. Clark, C.M., et al., *Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis*. Br J Dermatol, 1999. **141**(2): p. 279-82.
7. Fraser, A.D., et al., *A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis*. Ann Rheum Dis, 2005. **64**(6): p. 859-64.
8. Kivitz, A.J., et al., *Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials*. Clin Rheumatol, 2022. **41**(2): p. 499-511.

9. Korstanje, M.J., C.J. van Breda Vriesman, and W.J. van de Staak, *Cyclosporine and methotrexate: a dangerous combination*. J Am Acad Dermatol, 1990. **23**(2 Pt 1): p. 320-1.
10. Lowenthal, K.E., P.J. Horn, and R.E. Kalb, *Concurrent use of methotrexate and acitretin revisited*. J Dermatolog Treat, 2008. **19**(1): p. 22-6.
11. Mohanan, S., et al., *A retrospective analysis of combination methotrexate-cyclosporine therapy in moderate-severe psoriasis*. J Dermatolog Treat, 2014. **25**(1): p. 50-3.
12. Nash, P., et al., *Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance*. The Lancet Rheumatology, 2021. **3**(1): p. e28-e39.
13. Eric, P.N.P.R.L.G.A.M.C.R.K.K.E.L.M.-B.E.L.R.M.D.F.J.K.A., *Upadacitinib as monotherapy and in combination with non-biologic DMARDs for the treatment of psoriatic arthritis: subgroup analysis from two phase 3 trials*. EULAR 2021 Virtual Congress, 2022. **POS1035**.
14. Rattanakaemakorn, P., et al., *Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy*. Drug Des Devel Ther, 2021. **15**: p. 2299-2307.
15. Shivers, L. and M.E. Montanez-Wiscovich, *Verrucous psoriasis treated with methotrexate and acitretin combination therapy*. Cutis, 2019. **104**(6): p. E10-E12.
16. Wong, K.C. and K. Georgouras, *Low dose cyclosporin A and methotrexate in the treatment of psoriasis*. Acta Derm Venereol, 1999. **79**(1): p. 87.